M&A Deal Summary |
|
---|---|
Date | 2021-06-29 |
Target | BayMedica |
Sector | Life Science |
Buyer(s) | InMed Pharmaceuticals |
Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1981 |
Sector | Life Science |
Employees | 13 |
Revenue | 4M USD (2023) |
InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), and is developing IntegraSyn™ to produce pharmaceutical-grade cannabinoids. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. InMed Pharmaceuticals was formed in 1981 and is based in Vancouver, British Columbia.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
State (Nevada) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2021) | 1 of 1 |